LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On August8, 2017, Loxo Oncology,Inc. (“Loxo Oncology”) issued a press release announcing its financial results for the quarterly period ended June30, 2017. A copy of the press release is attached as Exhibit99.01 to this Current Report on Form8-K.

The information in this Item 2.02, including Exhibit99.01 to this Current Report on Form8-K, shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections11 and 12(a)(2)of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit99.01 shall not be incorporated by reference into any registration statement or other document filed by Loxo Oncology with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form8-K generally), except as shall be expressly set forth by specific reference in such filing.

Item 2.02 Financial Statements and Exhibits.

(d)Exhibits.

99.01

Press release issued by Loxo Oncology regarding its financial results for the quarterly period ended June30, 2017, dated August8, 2017.


Loxo Oncology, Inc. Exhibit
EX-99.01 2 a17-18952_1ex99d01.htm EX-99.01 Exhibit 99.01     Loxo Oncology Announces Second Quarter 2017 Financial Results   — Larotrectinib NDA Submission on Track for Year End 2017 / Early 2018 —   — Larotrectinib,…
To view the full exhibit click here

About LOXO ONCOLOGY,INC. (NASDAQ:LOXO)

Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.